Bayer Schering Pharma, part of Germany's Bayer group, says that its drug Zevalin ([90Y] ibritumomab tiusetan) significantly improves progression-free survival in patients suffering advanced follicular lymphoma. Trial data, presented at this year's American Society of Hematology meeting in Atlanta, showed that Zevalin conferred a mean PFS of 37 months, more than double the 13.7 month average achieved by subjects in the control group.
The reported study, known as FIT, examined Zevalin as a single-dose, first-line consolidation therapy in patients with advanced (stage III or IV) disease who have achieved some degree of remission after standard chemotherapy. Subgroup data revealed that, in subjects who had demonstrated a partial response, Zevalin treatment brought about PFS of 29.7 months versus 6.4 months in the comparator group, while those who had achieved completed remission after induction therapy saw average PFS of 54.6 months vs 29.9 months in the equivalent control arm.
Further analysis showed that radiation exposure associated with Zevalin treatment was within safe limits and that hematologic toxicity did not correlate with RM radiation dose estimates. This finding, which is consistent with previously-reported data, suggests that the drug can be safely administered to patients with low-tumor burden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze